Read by QxMD icon Read

endometrial cancer

M Janda, S McGrath, A Obermair
Uterine cancer is the fifth most common cancer in women worldwide with an estimated 320,000 annual diagnoses. Its most common form, endometrioid adenocarcinoma of the endometrium (endometrial adenocarcinoma [EAC]), is thought to develop through excessive proliferation of endometrial glands, and then increasing steadily in incidence. The current standard treatment for EAC is hysterectomy, which is often curative. However, it may be unacceptably expensive for women with severe medical comorbidities, those who are at risk of intra- and postoperative adverse events and those who desire fertility...
August 31, 2018: Best Practice & Research. Clinical Obstetrics & Gynaecology
Miseon Kim, Seul Lee, Wook Ha Park, Dong Hoon Suh, Kidong Kim, Yong Beom Kim, Jae Hong No
BACKGROUND: Bmi1, a polycomb group gene, is essential for self-renewal of stem cells and is frequently upregulated in various cancer cells. We aimed to investigate the effect of Bmi1 silencing on cancer stemness and chemosensitivity in endometrial cancer using targeted siRNA approach in HEC1A and Ishikawa cells. METHODS: Cell viability after treatment with Bmi1 siRNA was assessed using the MTT assay, and cell apoptosis was visualized using the TdT-mediated dUTP nick-end labeling (TUNEL) method...
September 19, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Kara A Michels, Britton Trabert
No abstract text is available yet for this article.
September 13, 2018: JAMA Oncology
Ellen C Grant
No abstract text is available yet for this article.
September 13, 2018: JAMA Oncology
Renata Rodrigues da Cunha Colombo Bonadio, Renata Gondim Meira Velame Azevedo, Guilherme Harada, Samantha Cabral Severino da Costa, Vanessa Costa Miranda, Daniela de Freitas, Elias Abdo Filho, Patricia Alves de Oliveira Ferreira, Flavia Gabrielli, Maria Del Pilar Estevez Diz
PURPOSE: The best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuvant chemotherapy seems to improve overall survival (OS) in locally advanced disease, the role of adding radiotherapy is not certain. We evaluated the outcomes of patients with high-risk endometrial cancer treated with adjuvant chemotherapy followed by radiotherapy. PATIENTS AND METHODS: We performed a retrospective analysis of patients with high-risk endometrial cancer (endometrioid histology stages III to IVA or carcinosarcoma, clear cell, or serous histology stages I to IVA) treated with adjuvant carboplatin and paclitaxel, followed by radiotherapy, from 2010 to 2017 at a Brazilian cancer center...
September 2018: Journal of Global Oncology
Rebecca Schneyer, Klaira Lerma
PURPOSE OF REVIEW: To review recent literature on health outcomes associated with use of hormonal contraception with a focus on breast cancer. RECENT FINDINGS: A large cohort study documented an increased risk of breast cancer among hormonal contraceptive users compared to those who had never used hormonal contraception. The overall relative risk of breast cancer among current or recent users was 1.2 [95% confidence interval (CI), 1.14-1.26]. Overall, this translates into one additional case of breast cancer for every 7690 users of hormonal contraception...
September 18, 2018: Current Opinion in Obstetrics & Gynecology
Taha Reşid Özdemir, Murat Alan, Muzaffer Sancı, Altuğ Koç
BACKGROUND: Lynch syndrome (LS), which is an inherited cancer disorder, has an increased lifetime risk for various cancers. Endometrial cancer (EC) is the most common extra-colonic cancer in LS. Guidelines recommend that patients with EC diagnosed under 50 years of age should be evaluated for LS. Molecular analysis of mismatch repair (MMR) genes and EPCAM gene is required for a definitive diagnosis of LS. AIMS: The purpose of this study was to report the mutation analysis of MMR genes using targeted next generation sequencing (NGS) in patients having EC diagnosed <50 years of age as the first study from Turkey, to our knowledge...
September 21, 2018: Balkan Medical Journal
Kevin Albuquerque, Junzo Chino, Ann Klopp, Mitchell Kamrava, Sushil Beriwal
No abstract text is available yet for this article.
November 1, 2018: International Journal of Radiation Oncology, Biology, Physics
Alexandra Huss, Gabriele Ihorst, Sylvia Timme-Bronsert, Annette Hasenburg, Martin K Oehler, Maximilian Klar
BACKGROUND: Despite the complexity of endometrial cancer (EC) tumor biology, treatment decisions are still mainly based on the post-surgical International Federation of Gynecology and Obstetrics (FIGO) stage. Prediction models considering more prognostic factors may represent a better risk assessment than FIGO stage alone. We tested the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram for the prediction of overall survival (OS) in a German EC population. METHODS: Overall, 454 EC patients (322 type I and 132 type II) who received primary surgical treatment at our department between 1991 and 2011 were included in the analysis with a dataset of 68 covariates...
September 20, 2018: Annals of Surgical Oncology
Rosa Autorino, Luca Tagliaferri, Maura Campitelli, Daniela Smaniotto, Alessia Nardangeli, Gian Carlo Mattiucci, Gabriella Macchia, Benedetta Gui, Maura Miccò, Floriana Mascilini, Gabriella Ferrandina, Gyorgy Kovacs, Vincenzo Valentini, Maria Antonietta Gambacorta
Purpose: To compare the survival and toxicity outcomes in patients with endometrial cancer treated with either high-dose-rate (HDR) or low-dose-rate (LDR) vaginal brachytherapy (VBT) following external beam radiotherapy (EBRT). Material and methods: From January 2000 to December 2014, patients with endometrial cancer after radical hysterectomy with/without pelvic and/or para-aortic lymphadenectomy were treated with adjuvant EBRT (45 Gy, 1.8 Gy/day to the whole pelvis) and subsequent VBT boost (HDR dose of 7 Gy in one fraction or LDR VBT dose of 25 Gy)...
August 2018: Journal of Contemporary Brachytherapy
L Adán-Merino, M Aldeguer-Martínez, E Alonso-Gamarra, F Valentín-Gómez, C Zaera-De la Fuente, S Martín-Chávarri
INTRODUCTION AND AIMS: Lynch-like syndrome is diagnosed when there is an expression deficit in DNA mismatch repair proteins but a normal genetic study. The behavior and management of that pathology are currently a subject of debate. We present herein the characteristics of patients with Lynch-like syndrome, together with a surveillance proposal. MATERIALS AND METHODS: Immunohistochemistry was carried out on families suspected of presenting with Lynch syndrome. Germline analysis was done if there was loss of mismatch repair protein expression and no BRAF mutation...
September 17, 2018: Revista de Gastroenterología de México
Soo-Min Kim, Kyung-A Hwang, Dal-Woong Choi, Kyung-Chul Choi
Cigarette smoke (CS) causes about 480,000 deaths each year worldwide and is well-known to have harmful effects on the human body, leading to heart disease, stroke, lung cancer, and cardiovascular problems. In the present study, the effects of acrylonitrile (AN), benzo(a)pyrene (B(a)P), formaldehyde (FOR), isoprene (ISO), nicotine-derived nitrosamine ketone (NNK), which are the main components of CS, on the proliferation, invasion, and the epithelial-mesenchymal transition (EMT) process of human Ishikawa endometrial adenocarcinoma cells were investigated...
September 17, 2018: Food and Chemical Toxicology
Gundula Behrens, Thomas Gredner, Christian Stock, Michael F Leitzmann, Hermann Brenner, Ute Mons
BACKGROUND: Excess weight, low physical activity, low intakes of dietary fiber, fruits, and vegetables, and high meat and salt intake increase cancer risk. METHODS: Numbers and proportions (population-attributable fractions, PAF) of incident cancer cases in Germany in 2018 attributable to these factors were estimated by sex and age groups for ages 35 to 84 years using population projections, national cancer incidence and exposure data, and published risk estimates...
September 3, 2018: Deutsches Ärzteblatt International
Tomohito Tanaka, Yoshito Terai, Kazuhiro Yamamoto, Takashi Yamada, Masahide Ohmichi
According to the sentinel node biopsy (SNB), systematic pelvic lymph node dissection (PLND) may not be needed for patients with early-stage endometrial cancer. On the other hand, imaging technology including fluorodeoxyglucose-positron emission tomography/computed tomography (FDG PET/CT) has been developing worldwide. The aim of this study was to evaluate the combined diagnostic accuracy of FDG PET/CT and SNB in the prediction of pelvic lymph node metastasis in endometrial cancer patients.One hundred twenty-one patients with endometrial cancer underwent FDG PET/CT before hysterectomy and received SNB followed by systematic PLND...
September 2018: Medicine (Baltimore)
Shuang Ma, Siddhartha Sen Sen, Rachel Jug, Xuefeng Zhang, Wan-Lin Zhang, Shuai Shen, Cheng-Qian Yu, Hong-Tao Xu, Lian-He Yang, Endi Wang
RATIONALE: Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with a dismal outcome. Most patients relapse in intracranial sites and <5% of patients relapse in extracranial sites. Here, we present the first case of PCNSL with an adrenal relapse. PATIENT CONCERNS: A 72-year-old woman, first presented 7 years ago with complaints of headache and dizziness. DIAGNOSES: Enhanced magnetic resonance imaging revealed the mass within the splenium of the corpus callosum...
September 2018: Medicine (Baltimore)
Steven R Goldstein
: In clinical practice, although only 3% to 7% of women with postmenopausal bleeding (PMB) will ultimately be found to have cancer, it is the clinician's responsibility to ensure that endometrial cancer is not present. The diagnostic evaluation of PMB has evolved greatly. This Practice Pearl addresses the appropriate evaluation of women with PMB.
September 17, 2018: Menopause: the Journal of the North American Menopause Society
Arielle L Heeke, Michael J Pishvaian, Filipa Lynce, Joanne Xiu, Jonathan R Brody, Wang-Juh Chen, Tabari M Baker, John L Marshall, Claudine Isaacs
Purpose: The prevalence of homologous recombination DNA damage repair (HR-DDR) deficiencies among all tumor lineages is not well characterized. Therapy directed toward homologous recombination DDR deficiency (HRD) is now approved in ovarian and breast cancer, and there may be additional opportunities for benefit for patients with other cancers. Comprehensive evaluations for HRD are limited in part by the lack of a uniform, cost-effective method for testing and defining HRD. Methods: Molecular profiles of 52,426 tumors were reviewed to identify pathogenic mutations in the HR-DDR genes ARID1A , ATM , ATRX , BAP1 , BARD1 , BLM , BRCA1/2 , BRIP1 , CHEK1/2 , FANCA/C/D2/E/F/G/L , MRE11A , NBN , PALB2 , RAD50 , RAD51 , RAD51B , or WRN ...
2018: JCO Precision Oncology
Mary Lourdes Montenegro, Camila M Bonocher, Juliana Meola, Rafael L Portella, Alfredo Ribeiro-Silva, Mariangela O Brunaldi, Rui Alberto Ferriani, Julio Cesar Rosa-E-Silva
OBJECTIVE: Endometriosis is characterized by the growth of endometrial tissue outside the uterine cavity. The prevalence of endometriosis among women experiencing pain, infertility, or both is as high as 35% to 50%. The most common symptoms of endometriosis are dysmenorrhea, dyspareunia, chronic pelvic pain, and infertility. Evidence has suggested that endometriosis symptoms result from a local inflammatory peritoneal reaction caused by ectopic endometrial implants that undergo cyclic bleeding...
September 19, 2018: Reproductive Sciences
Ilaria Colombo, Katherine C Kurnit, Shannon N Westin, Amit M Oza
The diffusion of high-throughput next-generation sequencing technologies has sustained massive parallel sequencing of tumor tissue providing a deep insight into tumor biology and advancement of personalized medicine. A substantial number of targeted agents have been investigated in gynecologic cancer and some have received U.S. Food and Drug Administration approval, like PARP inhibitors in ovarian cancer, bevacizumab in ovarian and cervical cancers, and pembrolizumab in microsatellite-unstable or mismatch repair-deficient endometrial cancer...
May 23, 2018: American Society of Clinical Oncology Educational Book
Ramez N Eskander
The care of patients with advanced-stage or recurrent endometrial, ovarian, and cervical cancer remains clinically challenging. Despite the identification of novel therapeutics and advancements in supportive care, survival outcomes have been relatively unchanged over the past decade. In addition to established genomic alterations and the contributions of the tumor microenvironment to cancer progression, epigenetic mechanisms have emerged as important contributors to gynecologic cancer progression. DNA methylation, histone modification, and noncoding RNA expression may be important contributors to disease initiation and progression and may represent novel therapeutic targets...
May 23, 2018: American Society of Clinical Oncology Educational Book
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"